Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on
heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are …

Currently, there is no completely effective therapy available for metastatic
phaeochromocytomas (PCCs) and paragangliomas. In this study, we explore new molecular …

Among the more promising treatments proposed for Alzheimer's disease (AD) and
Parkinson's disease (PD) are those reducing brain insulin resistance. The antidiabetics in …

Abstract Glucagon-like peptide 1 (GLP-1) is a growth factor. GLP-1 mimetics are on the
market as treatments for type 2 diabetes and are well tolerated. These drugs have shown …

Abstract Glucagon-like peptide-1 (GLP-1) is an incretin hormone that increases glucose-
dependent insulin secretion to reduce the glucose level. Liraglutide, a long-acting GLP-1 …

Recent studies indicate that glucagon-like peptide 1 (GLP-1) receptor agonists, currently
used in the management of type 2 diabetes, exhibit neurotrophic and neuroprotective effects …

Several randomized controlled trials have demonstrated the benefits of glucagon-like
peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this …

Glucagon-like peptide-1 (GLP-1) is released in response to meals and exerts important roles
in the maintenance of normal glucose homeostasis. GLP-1 is also important in the regulation …

Cerebral ischemia is a pathological condition resulting from the cessation or reduction of
blood supply to the cerebral arteries. Neurological deficits that are clinically relevant can …

The public and social health burdens of ischemic stroke have been increasing worldwide.
Hyperglycemia leads to a greater risk of stroke. This increased risk is commonly seen …